Covx Technologies Ireland Limited

Pfizer Corporation

Wyeth

Nicholas Gary Luksha

Mark John Pozzo

Nicholas W Warne

Palani Balu

Rory Francis Finn

Angela Kantor

Haim Moskowitz

Olivier Alexandre Laurent

Jin Xie

Moorthy Sitharamaiah Suriyanarayana Palanki

Nancy Jane Levin

Jie Huang

Gregory Allan Waszak

Joseph Patrick Martin, Jr

Gopinath Vedachalam Annathur

Li Li

Erin Soley

Edie Anna Neidhardt

The present invention provides a composition of the formula: [FGF21-1Linker]-[Ab]-[2-Linker-Ex4]; wherein FGF21 is an FGF21 homologue; and Ex4 is an Exendin4 homologue; and Ab is an aldolase catalytic antibody or antigen binding portion thereof; and the 1linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.

Anti-diabetic compounds

Growing community of inventors

North Andover, MA, United States of America

Nicholas Gary Luksha